BRPI0412567A - anticorpo humano isolado, método de tratamento de uma condição causada pela expressão aumentada de ngf ou pela sensibilidade aumentada ao ngf em um paciente, composição farmacêutica, método para detectar ngf em uma amostra biológica, molécula de ácido nucleico, célula hospedeira, linhagem celular isolada, agente de ligação especìfica em ngf, anticorpo humano isolado ou fragmento de imunoglobulina imunologicamente funcional ou um ligante de antìgeno do mesmo, polinucleotìdeo, vetor de expressão, medicamento para tratar um distúrbio doloroso ou uma condição associada com a expressão aumentada de ngf ou a sensibilidade aumentada ao ngf, e, uso de uma quantidade farmaceuticamente efetiva de anticorpo - Google Patents
anticorpo humano isolado, método de tratamento de uma condição causada pela expressão aumentada de ngf ou pela sensibilidade aumentada ao ngf em um paciente, composição farmacêutica, método para detectar ngf em uma amostra biológica, molécula de ácido nucleico, célula hospedeira, linhagem celular isolada, agente de ligação especìfica em ngf, anticorpo humano isolado ou fragmento de imunoglobulina imunologicamente funcional ou um ligante de antìgeno do mesmo, polinucleotìdeo, vetor de expressão, medicamento para tratar um distúrbio doloroso ou uma condição associada com a expressão aumentada de ngf ou a sensibilidade aumentada ao ngf, e, uso de uma quantidade farmaceuticamente efetiva de anticorpoInfo
- Publication number
- BRPI0412567A BRPI0412567A BRPI0412567-3A BRPI0412567A BRPI0412567A BR PI0412567 A BRPI0412567 A BR PI0412567A BR PI0412567 A BRPI0412567 A BR PI0412567A BR PI0412567 A BRPI0412567 A BR PI0412567A
- Authority
- BR
- Brazil
- Prior art keywords
- ngf
- increased
- expression
- treating
- human antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/48—Nerve growth factor [NGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
Abstract
"ANTICORPO HUMANO ISOLADO, MéTODO DE TRATAMENTO DE UMA CONDIçãO CAUSADA PELA EXPRESSãO AUMENTADA DE NGF OU PELA SENSIBILIDADE AUMENTADA AO NGF EM UM PACIENTE, COMPOSIçãO FARMACêUTICA, MéTODO PARA DETECTAR NGF EM UMA AMOSTRA BIOLóGICA, MOLéCULA DE áCIDO NUCLEICO, CéLULA HOSPEDEIRA, LINHAGEM CELULAR ISOLADA, AGENTE DE LIGAçãO ESPECìFICA EM NGF , ANTICORPO HUMANO ISOLADO OU FRAGMENTO DE IMUNOGLOBULINA IMUNOLOGICAMENTE FUNCIONAL OU UM LIGANTE DE ANTìGENO DO MESMO, POLINUCLEOTìDEO, VETOR DE EXPRESSãO, MEDICAMENTO PARA TRATAR UM DISTúRBIO DOLOROSO OU UMA CONDIçãO ASSOCIADA COM A EXPRESSãO AUMENTADA DE NGF OU A SENSIBILIDADE AUMENTADA AO NGF, E, USO DE UMA QUANTIDADE FARMACEUTICAMENTE EFETIVA DE ANTICORPO". Esta invenção refere-se aos anticorpos que interagem com ou se ligam em fator de crescimento de nervo (NGF) e neutralizam deste modo a função de NGF. A invenção também proporciona composições farmacêuticas de citados anticorpos e métodos para neutralizar a função de NGF, e particularmente para tratar distúrbios relacionados com NGF (por exemplo, dor crónica) por administração de uma quantidade farmaceuticamente efetiva de anticorpos anti-NGF. Métodos de detecção da quantidade de NGF em uma amostra usando anticorpos anti-NGF também são proporcionados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48743103P | 2003-07-15 | 2003-07-15 | |
PCT/US2004/022876 WO2005019266A2 (en) | 2003-07-15 | 2004-07-15 | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0412567A true BRPI0412567A (pt) | 2006-09-19 |
BRPI0412567B1 BRPI0412567B1 (pt) | 2017-03-21 |
Family
ID=34215825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0412567A BRPI0412567B1 (pt) | 2003-07-15 | 2004-07-15 | anticorpo isolado, ou fragmento de imunoglobulina imunologicamente funcional ou ligante de antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, medicamento para tratar um distúrbio doloroso ou uma condição associada com a expressão aumentada de ngf ou a sensibilidade aumentada ao ngf, e, uso de uma quantidade farmaceuticamente efetiva de anticorpo ou fragmento de imunoglobulina imunologicamente funcional ou ligante de antígeno do mesmo |
Country Status (31)
Country | Link |
---|---|
US (7) | US7601818B2 (pt) |
EP (2) | EP1648509B8 (pt) |
JP (8) | JP4489077B2 (pt) |
CN (3) | CN1849138B (pt) |
AR (2) | AR045056A1 (pt) |
AU (2) | AU2004267030B2 (pt) |
BR (1) | BRPI0412567B1 (pt) |
CA (1) | CA2534585C (pt) |
CY (1) | CY1113167T1 (pt) |
DK (1) | DK1648509T3 (pt) |
EA (2) | EA013614B1 (pt) |
ES (1) | ES2392954T3 (pt) |
GE (3) | GEP20146050B (pt) |
HK (2) | HK1088534A1 (pt) |
HR (2) | HRP20060033B1 (pt) |
IL (5) | IL173076A (pt) |
MA (1) | MA27952A1 (pt) |
ME (2) | ME02785B (pt) |
MX (2) | MX341869B (pt) |
NO (1) | NO20060381L (pt) |
NZ (3) | NZ544751A (pt) |
PL (1) | PL1648509T3 (pt) |
PT (1) | PT1648509E (pt) |
RS (2) | RS52332B (pt) |
SG (1) | SG10201404744RA (pt) |
SI (1) | SI1648509T1 (pt) |
TN (1) | TNSN06010A1 (pt) |
TW (4) | TWI503328B (pt) |
UA (2) | UA97086C2 (pt) |
WO (1) | WO2005019266A2 (pt) |
ZA (1) | ZA200600847B (pt) |
Families Citing this family (203)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0367170A (ja) * | 1989-08-04 | 1991-03-22 | Nippon Steel Corp | 金属試料中の微量炭素,硫黄,燐の分析方法 |
AU2003304238A1 (en) * | 2002-10-08 | 2005-01-13 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
UA80447C2 (en) * | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
NZ587852A (en) * | 2002-12-24 | 2012-02-24 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
WO2004073653A2 (en) * | 2003-02-19 | 2004-09-02 | Rinat Neuroscience Corp. | Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
GEP20146050B (en) * | 2003-07-15 | 2014-03-10 | Medarex Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
PT1732949E (pt) * | 2004-04-07 | 2010-03-23 | Univ Minnesota | Métodos de tratamento da dor associada ao cancro ósseo através da administração de um antagonista do factor de crescimento nervoso |
US7725178B2 (en) | 2004-06-30 | 2010-05-25 | Cedars-Sinai Medical Center | Method and system for the prediction of cardiac arrhythmias, myocardial ischemia, and other diseased condition of the heart associated with elevated sympathetic neural discharges |
ME00226B (me) * | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
TW200902555A (en) | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
PT1846451E (pt) * | 2005-01-24 | 2013-08-28 | Elan Pharma Int Ltd | Membros de ligação específica para ngf |
ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
MX2008001068A (es) * | 2005-07-29 | 2008-03-19 | Amgen Inc | Formulacion que inhibe la agregacion de proteina. |
BRPI0618315A2 (pt) * | 2005-11-07 | 2011-08-23 | Copenhagen University | seqüências de peptìdeo derivadas de neurotrofina |
US7822474B2 (en) * | 2005-11-30 | 2010-10-26 | Cedars-Sinai Medical Center | Methods for the prediction of arrhythmias and prevention of sudden cardiac death |
JP2010507366A (ja) * | 2006-10-19 | 2010-03-11 | メルク アンド カンパニー インコーポレイテッド | インターロイキン−13受容体α1の抗体アンタゴニスト |
CL2007003291A1 (es) * | 2006-11-15 | 2008-07-04 | Medarex Inc | Anticuerpo monoclonal humano aislado que enlaza la proteina btla o fragmentos del mismo; acido nucleico que lo codifica; metodo de produccion; composicion e inmunoconjugado que los comprende; y metodo para inhibir el crecimiento de celulas de tumor e |
WO2008079290A2 (en) * | 2006-12-21 | 2008-07-03 | Amgen Inc | Stable buffered formulations containing polypeptides |
NZ579010A (en) * | 2007-02-20 | 2012-03-30 | Anaptysbio Inc | Somatic hypermutation systems |
US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
MY153781A (en) * | 2007-08-10 | 2015-03-13 | Regeneron Pharma | High affinity human antibodies to human nerve growth factor |
AU2012216653B2 (en) * | 2007-08-10 | 2013-12-12 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
WO2009029795A1 (en) * | 2007-08-31 | 2009-03-05 | Amgen Inc. | Solid-state protein formulation |
WO2009043049A2 (en) | 2007-09-27 | 2009-04-02 | Amgen Inc. | Pharmaceutical formulations |
EP3381445B1 (en) | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
JP5737944B2 (ja) * | 2007-12-17 | 2015-06-17 | ファイザー・リミテッドPfizer Limited | 間質性膀胱炎の治療 |
CA2724279C (en) | 2008-05-13 | 2017-03-07 | Novimmune S.A. | Anti-il-6/il-6r antibodies and methods of use thereof |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
AU2009265808B2 (en) * | 2008-06-30 | 2014-10-23 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
US10188600B2 (en) * | 2008-09-19 | 2019-01-29 | Pfizer Inc. | Stable liquid antibody formulation |
SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
SG196855A1 (en) | 2008-10-22 | 2014-02-13 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
MX2011006108A (es) * | 2008-12-08 | 2011-11-18 | Vm Pharma Llc | Composiciones de inhibidores de los receptores tirosina quinasa. |
BRPI1014445A8 (pt) | 2009-05-04 | 2018-01-09 | Abbott Res Bv | anticorpos contra fator de crescimento de nervo (ngf) com estabilidade in vivo intensificada |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
CA2778105C (en) | 2009-10-23 | 2019-04-02 | Amgen Inc. | Vial adapter and system |
US10471212B2 (en) * | 2009-10-29 | 2019-11-12 | W. L. Gore & Associates, Inc. | Silicone free drug delivery devices |
US9597458B2 (en) | 2009-10-29 | 2017-03-21 | W. L. Gore & Associates, Inc. | Fluoropolymer barrier materials for containers |
TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
EP3216462A3 (en) | 2010-02-26 | 2017-12-20 | Novo Nordisk A/S | Stable antibody containing compositions |
DK3345615T3 (da) | 2010-03-01 | 2020-01-20 | Bayer Healthcare Llc | Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi) |
MX2012010728A (es) | 2010-03-17 | 2013-03-05 | Abbott Res Bv | Composiciones de anticuerpos de factor de anti-crecimiento de nervios (ngf). |
PT3205654T (pt) | 2010-05-20 | 2019-04-22 | Array Biopharma Inc | Compostos macrocíclicos como inibidores de cinases trk |
CA2800188A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
FI2575935T4 (fi) | 2010-06-07 | 2023-11-23 | Amgen Inc | Lääkeaineen vapautuslaite |
EP3333188B1 (en) | 2010-08-19 | 2022-02-09 | Zoetis Belgium S.A. | Anti-ngf antibodies and their use |
US11612697B2 (en) | 2010-10-29 | 2023-03-28 | W. L. Gore & Associates, Inc. | Non-fluoropolymer tie layer and fluoropolymer barrier layer |
JP6190723B2 (ja) | 2010-12-01 | 2017-08-30 | アルダーバイオ ホールディングス エルエルシー | 抗ngf組成物およびその使用 |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
CA2831100C (en) | 2011-03-31 | 2020-02-18 | Mark Dominis Holt | Vial adapter and system |
ES2725785T3 (es) | 2011-04-20 | 2019-09-27 | Amgen Inc | Aparato autoinyector |
WO2013009582A1 (en) | 2011-07-12 | 2013-01-17 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
DK2743348T3 (en) | 2011-08-11 | 2018-02-26 | Astellas Pharma Inc | Hitherto UNKNOWN ANTI-HUMAN NGF ANTIBODY |
EP3045190B1 (en) | 2011-10-14 | 2022-06-15 | Amgen Inc. | Injector and method of assembly |
US8926978B2 (en) | 2011-10-25 | 2015-01-06 | Anaptysbio, Inc. | Antibodies directed against nerve growth factor (NGF) |
WO2013176970A1 (en) | 2012-05-22 | 2013-11-28 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
US8945553B2 (en) | 2012-05-22 | 2015-02-03 | Bristol-Myers Squibb Company | Bispecific antibodies to IL-23 and IL-17A/F |
AU2013271564A1 (en) | 2012-06-06 | 2014-12-04 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
AU2013348071B2 (en) | 2012-11-21 | 2018-05-24 | Amgen Inc. | Drug delivery device |
JP6135161B2 (ja) * | 2013-02-08 | 2017-05-31 | アステラス製薬株式会社 | 新規抗ヒトngf抗体 |
US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
ES2973257T3 (es) | 2013-03-15 | 2024-06-19 | Amgen Inc | Casete de fármaco, autoinyector y sistema de autoinyector |
BR112015022042B1 (pt) | 2013-03-15 | 2023-01-10 | Amgen Inc | Injetor para injetar um produto terapêutico |
US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
TWI580452B (zh) | 2013-03-15 | 2017-05-01 | 安美基公司 | 用於注射器之匣盒、注射器及使用包括自動注射器及匣盒之設備之方法 |
ES2853748T3 (es) | 2013-03-22 | 2021-09-17 | Amgen Inc | Inyector y método de montaje |
US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
CA2923145A1 (en) | 2013-09-05 | 2015-03-12 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
WO2015039334A1 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
WO2015039333A1 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
EP3501575B1 (en) | 2013-10-24 | 2021-12-01 | Amgen Inc. | Drug delivery system with temperature-sensitive-control |
US11097055B2 (en) | 2013-10-24 | 2021-08-24 | Amgen Inc. | Injector and method of assembly |
CN106459182B (zh) * | 2013-12-30 | 2021-09-03 | 岸迈生物科技有限公司 | 串联fab免疫球蛋白及其用途 |
EP3102555B1 (en) | 2014-02-05 | 2021-05-12 | VM Oncology LLC | Compositions of compounds and uses thereof |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
WO2015143654A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
WO2015143653A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
WO2015143652A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
EP3139977B1 (en) | 2014-05-07 | 2021-02-17 | Amgen Inc. | Autoinjector with shock reducing elements |
MX2016014761A (es) | 2014-05-16 | 2017-05-25 | Amgen Inc | Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2). |
ES2981280T3 (es) | 2014-06-03 | 2024-10-08 | Amgen Inc | Sistema de administración de fármacos controlable y método de uso |
WO2016035052A1 (en) * | 2014-09-05 | 2016-03-10 | Nvip Pty Ltd | Anti-nerve growth factor antibodies for treating itching |
CA2957960C (en) | 2014-10-14 | 2023-08-22 | Amgen, Inc. | Drug injection device with visual and audible indicators |
TWI767858B (zh) | 2014-11-16 | 2022-06-11 | 美商亞雷生物製藥股份有限公司 | (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型 |
US11357916B2 (en) | 2014-12-19 | 2022-06-14 | Amgen Inc. | Drug delivery device with live button or user interface field |
US10799630B2 (en) | 2014-12-19 | 2020-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
CN104910274B (zh) * | 2015-02-12 | 2018-05-04 | 北京华安科创生物技术有限公司 | 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株 |
CN104774265B (zh) * | 2015-02-12 | 2018-05-04 | 北京华安科创生物技术有限公司 | 抗人神经生长因子的中和性单克隆抗体11f1及其杂交瘤细胞株 |
EP3258988B1 (en) | 2015-02-17 | 2019-08-28 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
ES2905870T3 (es) | 2015-02-27 | 2022-04-12 | Amgen Inc | Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja |
WO2016146730A1 (en) * | 2015-03-19 | 2016-09-22 | Neuheart S.R.L. | PEPTIDES HAVING TrkA-RECEPTOR-AGONISTIC ACTIVITY OR HAVING NGF-ANTAGONISTIC ACTIVITY |
MA41842A (fr) | 2015-03-31 | 2018-02-06 | Oblique Therapeutics Ab | Nouveaux procédés de sélection d'épitope |
WO2016161572A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
SG11201709589XA (en) | 2015-05-22 | 2017-12-28 | Astellas Pharma Inc | NOVEL ANTI-HUMAN NGF ANTIBODY Fab FRAGMENT |
GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
US11098079B2 (en) | 2015-08-13 | 2021-08-24 | Amgen Inc. | Charged depth filtration of antigen-binding proteins |
CA2995109A1 (en) | 2015-08-13 | 2017-02-16 | University Of Massachusetts | Human antibodies against rabies and uses thereof |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
ES2755717T3 (es) | 2015-12-09 | 2020-04-23 | Amgen Inc | Autoinyector con tapa de señalización |
WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
JOP20170013B1 (ar) | 2016-01-22 | 2021-08-17 | Merck Sharp & Dohme | أجسام xi مضادة لعامل مضاد للتجلط |
US11421028B2 (en) | 2016-02-06 | 2022-08-23 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
US11200298B2 (en) | 2016-03-15 | 2021-12-14 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
KR102400423B1 (ko) | 2016-04-04 | 2022-05-19 | 록쏘 온콜로지, 인코포레이티드 | (s)-n-(5-((r)-2-(2,5-디플루오로페닐)-피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-하이드록시피롤리딘-1-카복사미드의 액체 제형 |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
JP7309363B2 (ja) | 2016-05-13 | 2023-07-18 | アムジエン・インコーポレーテツド | バイアル・スリーブ組立体 |
US11238150B2 (en) | 2016-05-16 | 2022-02-01 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
LT3800189T (lt) | 2016-05-18 | 2023-10-10 | Loxo Oncology, Inc. | (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroksipirolidin-1-karboksamido gavimas |
US11541176B2 (en) | 2016-06-03 | 2023-01-03 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
CN109476758B (zh) | 2016-06-14 | 2023-05-23 | 默沙东有限责任公司 | 抗-凝血因子xi抗体 |
WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
WO2018027124A1 (en) | 2016-08-05 | 2018-02-08 | Medimmune, Llc | Anti-o2 antibodies and uses thereof |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
GB201614884D0 (en) * | 2016-09-01 | 2016-10-19 | Oblique Therapeutics Ab | Method |
GB201617002D0 (en) | 2016-10-06 | 2016-11-23 | Oblique Therapeutics Ab | Multi-protease method |
CA3039686A1 (en) | 2016-10-19 | 2018-04-26 | Medimmune, Llc | Anti-o1 antibodies and uses thereof |
US20200261643A1 (en) | 2016-10-25 | 2020-08-20 | Amgen Inc. | On-body injector |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
GB201621907D0 (en) * | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
MX2019008432A (es) | 2017-01-17 | 2019-11-18 | Amgen Inc | Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje. |
AU2018221351B2 (en) | 2017-02-17 | 2023-02-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
US11752258B2 (en) | 2017-02-17 | 2023-09-12 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
CA3050927A1 (en) | 2017-03-06 | 2018-09-13 | Brian Stonecipher | Drug delivery device with activation prevention feature |
IL268478B2 (en) | 2017-03-07 | 2023-10-01 | Amgen Inc | Inserting a needle using super pressure |
US11986624B2 (en) | 2017-03-09 | 2024-05-21 | Amgen Inc. | Insertion mechanism for drug delivery device |
AU2018235928B2 (en) | 2017-03-14 | 2023-09-21 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
SG11201907676PA (en) | 2017-03-28 | 2019-09-27 | Amgen Inc | Plunger rod and syringe assembly system and method |
EP3634539A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
CN110709121B (zh) | 2017-06-08 | 2022-06-24 | 安进公司 | 扭矩驱动式药物递送装置 |
AU2018288604B2 (en) | 2017-06-22 | 2023-12-21 | Amgen Inc. | Device activation impact/shock reduction |
US11395880B2 (en) | 2017-06-23 | 2022-07-26 | Amgen Inc. | Electronic drug delivery device |
WO2019014014A1 (en) | 2017-07-14 | 2019-01-17 | Amgen Inc. | NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM |
US11672733B2 (en) | 2017-07-21 | 2023-06-13 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
EP3658206A1 (en) | 2017-07-25 | 2020-06-03 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
JP2020528296A (ja) | 2017-07-25 | 2020-09-24 | アムジエン・インコーポレーテツド | ギヤモジュールを有する薬物送達デバイス及び関連する組立方法 |
MA49838A (fr) | 2017-08-09 | 2020-06-17 | Amgen Inc | Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre |
US11077246B2 (en) | 2017-08-18 | 2021-08-03 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
MA50611A (fr) | 2017-10-04 | 2020-08-12 | Amgen Inc | Adaptateur d'écoulement destiné à un dispositif d'administration de médicament |
MA50614A (fr) | 2017-10-06 | 2020-08-12 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé |
IL273323B2 (en) | 2017-10-09 | 2024-10-01 | Amgen Inc | Drug delivery device with drive assembly and related assembly method |
MA50528A (fr) | 2017-11-03 | 2020-09-09 | Amgen Inc | Systèmes et approches pour stériliser un dispositif d'administration de médicament |
MA50569A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Ensembles de remplissage-finition et procédés associés |
EP3706830B1 (en) | 2017-11-06 | 2024-08-07 | Amgen Inc. | Drug delivery device with placement and flow sensing |
EP3706826A1 (en) | 2017-11-10 | 2020-09-16 | Amgen Inc. | Plungers for drug delivery devices |
MX2020005066A (es) | 2017-11-16 | 2020-08-20 | Amgen Inc | Autoinyector con deteccion de detencion y punto final. |
CN111278487B (zh) | 2017-11-16 | 2022-06-24 | 安进公司 | 用于药物递送装置的门闩锁机构 |
AR114110A1 (es) | 2018-02-28 | 2020-07-22 | Lilly Co Eli | Anticuerpo anti-trka |
CN111819197A (zh) | 2018-03-12 | 2020-10-23 | 硕腾服务有限责任公司 | 抗ngf抗体及其方法 |
KR20200135781A (ko) | 2018-03-26 | 2020-12-03 | 암젠 인크 | 세포 배양에서 생산된 항체의 총 비푸코실화 당형태 |
CN108623687A (zh) | 2018-04-17 | 2018-10-09 | 中山康方生物医药有限公司 | 神经生长因子的单克隆抗体及其编码基因和应用 |
CN112074541A (zh) | 2018-05-03 | 2020-12-11 | 上海岸迈生物科技有限公司 | Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白 |
WO2019221097A1 (ja) | 2018-05-15 | 2019-11-21 | アステラス製薬株式会社 | 抗ヒトngf抗体又はその抗原結合フラグメントを有効成分とする心房細動の抑制用医薬組成物 |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
WO2020023451A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
MX2021000748A (es) | 2018-07-24 | 2021-03-26 | Amgen Inc | Dispositivos de suministro para administrar farmacos. |
CA3103105A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
MA53724A (fr) | 2018-09-24 | 2021-12-29 | Amgen Inc | Systèmes et procédés de dosage interventionnel |
WO2020068476A1 (en) | 2018-09-28 | 2020-04-02 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
MX2021003492A (es) | 2018-10-02 | 2021-06-18 | Amgen Inc | Sistemas de inyeccion para la administracion de farmacos con transmision de fuerza interna. |
JP7547325B2 (ja) | 2018-10-05 | 2024-09-09 | アムジエン・インコーポレーテツド | 投薬量インジケータを有する薬物送達デバイス |
IT201800009384A1 (it) | 2018-10-11 | 2020-04-11 | Cosmo Srl | Peptide for cosmetic application |
EP3866890A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Drug delivery device having damping mechanism |
TWI846741B (zh) | 2018-10-15 | 2024-07-01 | 美商安進公司 | 用於藥物遞送裝置之平台組裝方法 |
MA54048A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
AU2019370159A1 (en) | 2018-11-01 | 2021-04-22 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
US20220160972A1 (en) | 2019-04-24 | 2022-05-26 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
EP4017560A2 (en) | 2019-08-23 | 2022-06-29 | Amgen, Inc | Drug delivery device with configurable needle shield engagement components and related methods |
KR20220069982A (ko) | 2019-09-26 | 2022-05-27 | 암젠 인크 | 항체 조성물의 생산 방법 |
CN113527483B (zh) * | 2020-04-17 | 2023-09-22 | 珠海泰诺麦博制药股份有限公司 | 抗人神经生长因子的抗体 |
CN113527482B (zh) * | 2020-04-17 | 2023-07-21 | 珠海泰诺麦博制药股份有限公司 | 抗人神经生长因子的抗体 |
EP4157881A4 (en) * | 2020-05-27 | 2024-10-09 | Staidson Beijing Biopharmaceuticals Co Ltd | ANTIBODIES THAT SPECIFICALLY RECOGNIZE NERVE GROWTH FACTOR AND THEIR USES |
AR122141A1 (es) | 2020-05-28 | 2022-08-17 | Lilly Co Eli | Inhibidor de trka |
US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
AU2020204105B2 (en) * | 2020-06-19 | 2023-06-08 | Ampsource Biopharma Shanghai Inc. | Anti-human ngf antibodies and methods using same |
US11655292B2 (en) | 2020-06-23 | 2023-05-23 | Ampsource Biopharma Shanghai Inc. | Anti-human NGF antibodies and methods using same |
AU2021360897A1 (en) | 2020-10-15 | 2023-05-25 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
IL307418A (en) | 2021-05-21 | 2023-12-01 | Amgen Inc | A method for optimizing a filling recipe for a drug container |
CA3222409A1 (en) | 2021-06-07 | 2022-12-15 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
EP4413377A1 (en) | 2021-10-05 | 2024-08-14 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023111153A1 (en) * | 2021-12-16 | 2023-06-22 | Intervet International B.V. | Caninized antibodies to human ngf |
WO2023212586A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Methods for selecting patients for treatment with an ngf antagonist |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4230691A (en) * | 1978-05-23 | 1980-10-28 | The Massachusetts General Hospital | Nerve growth factor antibody and process |
GB2077573A (en) | 1980-06-10 | 1981-12-23 | Kangol Magnet Ltd | Vehicle seat belt connection device |
US4786593A (en) * | 1985-04-16 | 1988-11-22 | Wistar Institute Of Anatomy And Biology | Diagnostic method for detection of neural crest disease |
JP2969647B2 (ja) | 1988-09-14 | 1999-11-02 | 東ソー株式会社 | モノクローナル抗体、それからなる阻害剤及びそれを用いた測定方法 |
SE465573B (sv) | 1989-03-14 | 1991-09-30 | Lope Medicine Ab | Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor |
JPH03163095A (ja) | 1989-08-28 | 1991-07-15 | Takeda Chem Ind Ltd | ヒト神経成長因子の部分ペプチド、抗体およびその用途 |
DE69031726T2 (de) | 1989-08-28 | 1998-03-12 | Takeda Chemical Industries Ltd | Antikörper, ihre Herstellung und Verwendung |
US5656435A (en) * | 1989-08-28 | 1997-08-12 | Takeda Chemical Industries, Ltd. | Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof |
JP3232415B2 (ja) | 1990-08-29 | 2001-11-26 | 武田薬品工業株式会社 | モノクローナル抗体,その製造法および用途 |
US6300129B1 (en) * | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
JPH06317587A (ja) | 1990-08-31 | 1994-11-15 | Takeda Chem Ind Ltd | 抗体およびその用途 |
US5147294A (en) * | 1990-10-01 | 1992-09-15 | Trustees Of Boston University | Therapeutic method for reducing chronic pain in a living subject |
JPH0576384A (ja) | 1991-09-20 | 1993-03-30 | Hitachi Ltd | 抗ヒト神経成長因子モノクローナル抗体 |
JP3519096B2 (ja) | 1992-07-02 | 2004-04-12 | 武田薬品工業株式会社 | モノクローナル抗体、ハイブリドーマおよびそれらの用途 |
US5877016A (en) * | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US5844092A (en) * | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
GB9616105D0 (en) * | 1996-07-31 | 1996-09-11 | Univ Kingston | TrkA binding site of NGF |
US7322122B2 (en) | 1997-01-15 | 2008-01-29 | Draka Comteq B.V. | Method and apparatus for curing a fiber having at least two fiber coating curing stages |
IL147765A0 (en) | 1999-07-29 | 2002-08-14 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES TO HER2/neu |
PL202369B1 (pl) * | 1999-08-27 | 2009-06-30 | Genentech Inc | Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało |
US6548062B2 (en) * | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
FR2807660A1 (fr) * | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
KR20100132559A (ko) * | 2001-05-30 | 2010-12-17 | 제넨테크, 인크. | 다양한 질환의 치료에 유용한 항-엔지에프 항체 |
US6881557B2 (en) * | 2001-07-12 | 2005-04-19 | Arrowsmith Technologies Llp | Super humanized antibodies |
WO2003033538A1 (fr) | 2001-10-15 | 2003-04-24 | Kirin Beer Kabushiki Kaisha | Anticorps anti-hlr-dr |
JP2005516965A (ja) * | 2001-12-28 | 2005-06-09 | アブジェニックス・インコーポレーテッド | 抗muc18抗体を使用する方法 |
US6919426B2 (en) * | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
KR101080716B1 (ko) * | 2002-10-08 | 2011-11-07 | 리나트 뉴로사이언스 코퍼레이션 | 신경성장인자 길항제를 투여함에 의한 수술-후 통증의치료방법 및 그를 함유하는 조성물 |
NZ587852A (en) * | 2002-12-24 | 2012-02-24 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
EP1468999A1 (en) * | 2003-03-20 | 2004-10-20 | MyoContract Ltd. | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
GEP20146050B (en) * | 2003-07-15 | 2014-03-10 | Medarex Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
PT1846451E (pt) | 2005-01-24 | 2013-08-28 | Elan Pharma Int Ltd | Membros de ligação específica para ngf |
-
2004
- 2004-07-15 GE GEAP200411890A patent/GEP20146050B/en unknown
- 2004-07-15 EA EA200600254A patent/EA013614B1/ru not_active IP Right Cessation
- 2004-07-15 EA EA201000245A patent/EA030259B8/ru not_active IP Right Cessation
- 2004-07-15 UA UAA200601428A patent/UA97086C2/uk unknown
- 2004-07-15 ME MEP-2010-201A patent/ME02785B/me unknown
- 2004-07-15 RS RS20060022A patent/RS52332B/en unknown
- 2004-07-15 GE GEAP200411194A patent/GEP20196963B/en unknown
- 2004-07-15 SG SG10201404744RA patent/SG10201404744RA/en unknown
- 2004-07-15 ME MEP-315/08A patent/MEP31508A/xx unknown
- 2004-07-15 TW TW101137958A patent/TWI503328B/zh not_active IP Right Cessation
- 2004-07-15 MX MX2010012581A patent/MX341869B/es unknown
- 2004-07-15 RS RS20100555A patent/RS20100555A/en unknown
- 2004-07-15 UA UAA201109302A patent/UA115960C2/uk unknown
- 2004-07-15 NZ NZ544751A patent/NZ544751A/en not_active IP Right Cessation
- 2004-07-15 TW TW104117245A patent/TWI635096B/zh not_active IP Right Cessation
- 2004-07-15 ES ES04778409T patent/ES2392954T3/es not_active Expired - Lifetime
- 2004-07-15 EP EP04778409A patent/EP1648509B8/en not_active Expired - Lifetime
- 2004-07-15 BR BRPI0412567A patent/BRPI0412567B1/pt not_active IP Right Cessation
- 2004-07-15 SI SI200431959T patent/SI1648509T1/sl unknown
- 2004-07-15 EP EP10011652A patent/EP2364728A1/en not_active Withdrawn
- 2004-07-15 CN CN2004800262422A patent/CN1849138B/zh not_active Expired - Fee Related
- 2004-07-15 DK DK04778409.5T patent/DK1648509T3/da active
- 2004-07-15 TW TW093121202A patent/TWI385180B/zh not_active IP Right Cessation
- 2004-07-15 CA CA2534585A patent/CA2534585C/en not_active Expired - Fee Related
- 2004-07-15 MX MXPA06000583A patent/MXPA06000583A/es active IP Right Grant
- 2004-07-15 CN CN201110291430.XA patent/CN102358903B/zh not_active Expired - Fee Related
- 2004-07-15 NZ NZ599196A patent/NZ599196A/en not_active IP Right Cessation
- 2004-07-15 AR ARP040102501A patent/AR045056A1/es not_active Application Discontinuation
- 2004-07-15 GE GEAP20049228A patent/GEP20104887B/en unknown
- 2004-07-15 TW TW097142179A patent/TWI382031B/zh not_active IP Right Cessation
- 2004-07-15 CN CN201110291428.2A patent/CN102408483B/zh not_active Expired - Fee Related
- 2004-07-15 US US10/891,658 patent/US7601818B2/en not_active Expired - Fee Related
- 2004-07-15 NZ NZ588527A patent/NZ588527A/en not_active IP Right Cessation
- 2004-07-15 WO PCT/US2004/022876 patent/WO2005019266A2/en active Application Filing
- 2004-07-15 JP JP2006520361A patent/JP4489077B2/ja not_active Expired - Fee Related
- 2004-07-15 AU AU2004267030A patent/AU2004267030B2/en not_active Ceased
- 2004-07-15 PT PT04778409T patent/PT1648509E/pt unknown
- 2004-07-15 PL PL04778409T patent/PL1648509T3/pl unknown
-
2006
- 2006-01-10 IL IL173076A patent/IL173076A/en active IP Right Grant
- 2006-01-13 TN TNP2006000010A patent/TNSN06010A1/en unknown
- 2006-01-24 NO NO20060381A patent/NO20060381L/no not_active Application Discontinuation
- 2006-01-24 HR HRP20060033AA patent/HRP20060033B1/hr not_active IP Right Cessation
- 2006-01-30 ZA ZA200600847A patent/ZA200600847B/xx unknown
- 2006-02-15 MA MA28809A patent/MA27952A1/fr unknown
- 2006-08-07 HK HK06108730.2A patent/HK1088534A1/xx not_active IP Right Cessation
-
2007
- 2007-04-10 HK HK07103693.7A patent/HK1096310A1/xx not_active IP Right Cessation
- 2007-06-22 US US11/767,326 patent/US7795413B2/en not_active Expired - Fee Related
-
2008
- 2008-11-25 US US12/277,919 patent/US8198410B2/en not_active Expired - Fee Related
-
2009
- 2009-07-03 JP JP2009159335A patent/JP2010006812A/ja active Pending
-
2010
- 2010-02-15 JP JP2010030722A patent/JP5264798B2/ja not_active Expired - Fee Related
- 2010-03-04 AR ARP100100652A patent/AR075790A2/es not_active Application Discontinuation
- 2010-05-28 AU AU2010202177A patent/AU2010202177B2/en not_active Ceased
- 2010-07-05 IL IL206823A patent/IL206823A0/en unknown
- 2010-08-18 US US12/859,246 patent/US8106167B2/en not_active Expired - Fee Related
- 2010-09-13 US US12/880,961 patent/US20110091476A1/en not_active Abandoned
-
2011
- 2011-07-25 IL IL214280A patent/IL214280A0/en unknown
- 2011-07-25 IL IL214281A patent/IL214281A/en active IP Right Grant
-
2012
- 2012-03-12 JP JP2012054665A patent/JP2012161316A/ja active Pending
- 2012-08-22 JP JP2012183471A patent/JP2012250986A/ja not_active Withdrawn
- 2012-10-02 CY CY20121100912T patent/CY1113167T1/el unknown
- 2012-10-31 HR HRP20120882TT patent/HRP20120882T1/hr unknown
-
2014
- 2014-10-31 JP JP2014222225A patent/JP5965964B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-04 JP JP2015042006A patent/JP2015155413A/ja not_active Withdrawn
- 2015-10-06 IL IL241874A patent/IL241874A0/en unknown
-
2016
- 2016-01-19 US US15/000,771 patent/US20160237147A1/en not_active Abandoned
- 2016-04-22 US US15/136,832 patent/US20160304596A1/en not_active Abandoned
- 2016-12-28 JP JP2016254911A patent/JP2017079782A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0412567A (pt) | anticorpo humano isolado, método de tratamento de uma condição causada pela expressão aumentada de ngf ou pela sensibilidade aumentada ao ngf em um paciente, composição farmacêutica, método para detectar ngf em uma amostra biológica, molécula de ácido nucleico, célula hospedeira, linhagem celular isolada, agente de ligação especìfica em ngf, anticorpo humano isolado ou fragmento de imunoglobulina imunologicamente funcional ou um ligante de antìgeno do mesmo, polinucleotìdeo, vetor de expressão, medicamento para tratar um distúrbio doloroso ou uma condição associada com a expressão aumentada de ngf ou a sensibilidade aumentada ao ngf, e, uso de uma quantidade farmaceuticamente efetiva de anticorpo | |
BRPI0408315A (pt) | anticorpo isolado, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos de produzir um anticorpo, de gerar um anticorpo ou fragmento de ligação de antìgeno, de regular uma resposta imune, de tratar ou prevenir um distúrbio associado com célula imune em um paciente, de tratar ou prevenir um distúrbio hiperproliferativo em um paciente, e, kit de diagnóstico | |
BRPI0412885A (pt) | polipeptìdios, agentes de ligação especìficos, moléculas de ácido nucleico e linhas de células isoladas, células hospedeiras, composições e anticorpo ou domìnio de ligação de antìgeno e métodos de tratamento de cáncer e de tumor sólido num paciente, de detecção do nìvel do fator de crescimento hepatócito (hgf) numa amostra, de obtenção de anticorpo e de inibição da ligação de hgf a met e de diminuição ou prevenção da ligação de qualquer um dos agentes de ligação especìficos ao fator de crescimento hepatócito (hgf) | |
BR0210579A (pt) | Anticorpos, cadeias pesadas e leves, composição farmacêutica e métodos de detecção do nìvel de opgl em amostra biológia e de tratamento | |
BRPI0410129B8 (pt) | anticorpo anti-cs1 isolado, fragmento de ligação de antígeno, composto conjugado e composição farmacêutica | |
BR0315161A (pt) | Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição | |
BRPI0314038B8 (pt) | anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica | |
BRPI0418695A (pt) | uso terapêutico de anticorpos anti-cs1 | |
KR101155294B1 (ko) | 면역특이적으로 BLyS에 결합하는 항체 | |
BRPI0416603A (pt) | anticorpo que se liga ao receptor interleucina-4 (il-4) humano | |
BRPI0606148A2 (pt) | anticorpos monoclonais neutralizantes contra a sìndrome respiratória aguda grave associada com o coronavìrus | |
UA99094C2 (ru) | Способ лечения пациента с системной красной волчанкой | |
Aebig et al. | Formulation of vaccines containing CpG oligonucleotides and alum | |
ME00226B (me) | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade | |
WO2003016464A3 (en) | Cancer specific oligosaccharide sequences and use thereof | |
WO2003016915A8 (en) | Tumor specific oligosaccharide sequences and use thereof | |
BRPI0411510A (pt) | proteìna, composição farmacêutica, uso da proteìna, polipeptìdeo, uso do mesmo, vetor, ácido nucleico, célula hospedeira, soro policlonal, anticorpo monoclonal, uso de um soro policlonal ou de um anticorpo monoclonal, método para alvejar in vitro uma molécula de interesse com as células que expressam cd11b, células que expressam cd11b, produto de terapia celular para imunizar um ser humano ou um animal contra um antìgeno uso de células que expressam cd11b, e, método para imunizar um paciente contra antìgeno | |
BR0207528A (pt) | Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo | |
BR0116763A (pt) | Anticorpos humanos especìficos para terapia seletiva do c ncer | |
El Hafny et al. | Intraspecific variability and pharmacokinetic characteristics of Androctonus mauretanicus mauretanicus scorpion venom | |
WO2005016236A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
WO2010036031A3 (en) | Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same | |
WO2001041813A3 (en) | Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof | |
BR9910589A (pt) | Anticorpo humanizado, processo para produzir anticorpo humanizado vtm1-1, composição farmacêutica, e, processo para tratar um paciente sofrendo ou em risco dos efeitos tóxicos de uma verotoxina, e, linhagem de célula | |
WO2002014475A3 (en) | Quantitative assessment of erbb/her receptors in biological fluids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: AMGEN INC. (US) , MEDAREX, L.L.C. (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B25A | Requested transfer of rights approved | ||
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |